In the second year of the study, investigators rerandomized patients who had been receiving vehicle to an active arm
of the study, and patients with less than 25% improvement on a facial vitiligo scoring scale were rerandomized to one of the different doses.
Endoscopic recurrence rates were found to be 5.2% (10/192) in the active arm
and 21% (37/176) in the control arm at the first surveillance procedure.
In the active arm
, individuals will be provided first with BAN2401 with the goal to clear amyloid deposits and A[beta] protofibrils from the brain, after which they will be maintained on elenbecestat with the aim of decreasing the production of A[beta] and preventing the reaccumulation of amyloid plaques and protofibrils.
In all, 1,715 women in the active arm
and 1,705 in the placebo arm were included in the outcomes analyses.
Today, The Corporate Social Responsibility Program of TPB is currently the most active arm
of the agency in promoting sustainable tourism.
To do this, the robot moved the nondominant arm passively to a position and the subject then placed the index finger of their opposite active arm
, represented by a white circle in the virtual environment, into a red target presented in a mirrored position in the workspace.
Let there be no misunderstanding, people trafficking and smuggling is no less than an active arm
of the slave trade.
The "placebo effect" encompassed all "nonspecific effects" that did not depend on the treatment in the active arm
. The "powerful placebo" became a hodge-podge of nonlinear, difficult to quantify, remnants collected under the rubric of the dummy control of an RCT.
Results: A total of 123 cases of recurrent abortion (RA) were recruited and identified for registration (Point Estimate of Incidence) among them n=67 mothers in the active arm
and n=56 in placebo arm.
The study also found consistency of effect among responders, with the percentage of episodic subjects in the active arm
who experienced success for more than 50% of the attacks was 34.2% versus 14.9% among the sham group (p=0.04).
The concept was that if the initial 18 months of drug treatment of patients in the active arm
produced true disease modification, the difference in efficacy between the active and placebo arms in patients with mild disease seen at 18 months should remain roughly constant over subsequent months of solanezumab treatment of all patients, with no catchup by the patients first randomized to placebo and hence no convergence of the outcome curves of the two treatment subgroups: patients on continuous solanezumab treatment and patients who first received placebo and then had a delayed start on solanezumab.
No patient had a serious adverse event on active treatment, and two patients in the active arm
discontinued because of an adverse event.